S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer

BACKGROUND: CDK4/6 inhibitors combined with endocrine therapy has become the preferred treatment approach for patients with estrogen receptor-positive metastatic breast cancer. However, the predictive biomarkers and mechanisms of innate resistance to CDK4/6 inhibitors remain largely unknown. We soug...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Hongnan, Liu, Xuefeng, Xue, Yu, Chen, Hongyan, Guo, Shichao, Li, Zhangfu, Wang, Shuang, Li, Caiming, Han, Jiashu, Fu, Ming, Song, Yongmei, Li, Dan, Ma, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426012/
https://www.ncbi.nlm.nih.gov/pubmed/36042494
http://dx.doi.org/10.1186/s12943-022-01642-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426012/
https://www.ncbi.nlm.nih.gov/pubmed/36042494
http://dx.doi.org/10.1186/s12943-022-01642-5

Ejemplares similares